Page 245 - Mercy MOR All Regions_FinalwithVideo

Key Performance Indicators Metric 3,193 $1,691 ($21) % Variance -7.0% $14,263,273
St. Joseph Warren Hospital
Variance
Actual
Budget
Prior
5.2%
$3,606,823
$185,868
$3,281,756
$3,420,955
Supply Expense
$14,433,658
($1,009,662)
Net Patient Revenue
$13,423,996
0.5%
2.0%
25.0%
25.5%
23.0%
Supply Expense % Net Patient Revenue
$1,712
-1.2%
Supply Expense per EIPA
$1,594
(43)

Total Admissions
798
-5.4%
786
755
Total Patient Days
3,441
-2.8%

(93)
3,286
1,999
2,133
Total EIPAs
-6.3%

(134)
2,059
69
116
-40.5%
IP Surgeries
126
(47)

(60)
460
400
OP Surgeries
-18.4%
575

469

Total Surgeries
Site Performance Summary (106) -13.0% 424 550
Overall supply expense was under budget by $176K (4.9%) on softer than expected surgical volume. Admissions were 5.4% under
budget while patient days lagged by 2.8%. Resultant EIPA shortfall of 6.3% tracks closely with the overall supply expense variance.
Disappointing surgical volume for the month resulted in a favorable variance on Medical Surgical supplies of $167K (20.7%) and Implants
$129K (26%). Flu-related lab testing supplies resulted in a $28K variance to budget and is expected to continue for the balance of the
season. Interventional Radiology expense was under budget by a wide margin, $42K (63%) on fewer procedures, most notably a
reduction peripheral vascular. Drugs were over budget $38K (1.9%) on an increase in antineoplastic agents including Rituxan, Optivo,
and Herceptin.
St. Joseph Warren Hospital Leader's Summary
Key Challenges
Intuitive spend of $39,155 was an increase over PY's $25K, however robotic procedure count was
up by 21 cases (210%)
Special Procedures was $42K (63%) under budget on a significant decrease in peripheral vascular
procedures. ED exceeded budget by $5K (12.4%) on volume that exceeded budget by 10.7% |
Med/Surg
Chemistry: $34K (50%) under budget - noted a $50K accrual reversal during the period along
with a significant overage in the General Lab account
ED exceeded budget by $5K (12.4%) on volume that exceeded budget by 10.7%
The following drugs showed marked increases vs. January, 2018: Rituxan (up $24K, 34%), Opdivo
($93,000 - new item), Avastin ($12K, 22%)
Increases also noted for Remicade (Antirheumatic $62K, 43%) and Digifab (Antitoxin $25K - new
Rx
item %)
Orthopedic implants came in $55K under budget on comparatively low procedure volume, 30
cases compared with 37 PY. Cost per total knee and hip both improved vs. PY: TKA $4,246 vs.
$4871 THA $4,970 vs. $5,550
Implants Spinal implants were under budget by $68K (92.1%) on one primary neurostim implants for the
month. The facility did, however, implant five pain pumps totaling $47.500.
Two EVAR/AAA cases were perfomed during the month for a total of $48,993.
Laboratory up significantly on flu-related test volume - $45K variance. Requested to have $17K in
flu tests accrued as arrived 1/31. It should be noted that some items in this category were
previously booked to MedSurg expense.
Other Expenses IV and IV sets exceed budget due in most part to a change in coding for IV catheters and start
kits.
Actions Taken/Planned:
Continue to closely monito flu item availability and resultant spend. Reduce reorders to coincide
with the end of flu season.
Supply Chain and Admin to engage with new neuro provider to impact choice of neurostimulator
vendor.